Peptide register

Small-molecule NNMT inhibitor studied preclinically; no registered human trials, no approval.

Synthetic analogue of parathyroid hormone-related protein (1-34); approved prescription medicine for osteoporosis.

Prescription-only in the US, EU, UK, Switzerland, Australia and Japan; not approved in Canada; approved for men only in the US

Proapoptotic peptidomimetic; early trial work stopped, no approval and no active development.

AMP-activated protein kinase activator trialled in the 1990s; not approved in any market.

Recombinant follistatin isoform sold for laboratory use; the only human data come from gene therapy, not the protein.

D-retro-inverso peptide studied in rodent senescence models; no approval in any market.

Endogenous tripeptide antioxidant sold as an oral supplement; injectable forms are unapproved.

Injectable forms hold no marketing authorisation

Amino acid derivative sold as a supplement; a prescription form exists for carnitine deficiency.

A prescription levocarnitine medicine exists for carnitine deficiency

Pineal hormone: prescription-only in the EU, UK, Switzerland and Canada, a supplement without FDA approval in the US, injectable nowhere.

Status differs by country and form: a prescription medicine in the EU, UK, Switzerland and Canada, a dietary supplement without FDA approval in the US; injectable forms hold no marketing authorisation anywhere

Coenzyme sold as an oral supplement; an injectable form is approved only in China.

Injectable form approved only in China (prescription); unauthorised elsewhere

p53-derived peptide studied in cell and animal models only; never in a clinical trial, and the subject of an FDA safety warning.

Small-molecule estrogen-related receptor agonist; preclinical only, no approval anywhere.

Recombinant parathyroid hormone fragment (1-34); approved prescription medicine for osteoporosis.

Fully synthetic 28-amino-acid peptide identical to a natural thymic peptide; prescription-only medicine in Italy and China.

Approved only in Italy and China; not approved in the US, the EU centrally, the UK, Canada, Switzerland, Japan or Australia

Zinc-dependent thymic nonapeptide hormone described in the 1970s; not approved as a medicine anywhere.

Studied in small clinical series in the 1980s; no marketing authorisation and no active development

Cyanocobalamin, a synthetic form of vitamin B12 and not a peptide; listed because it is mixed into compounded weight-loss injections.

Varies by country and form: injections are prescription-only in the US, Switzerland and the UK, pharmacy-only without prescription in Germany; oral forms are sold as supplements